In obese male primates, combining a treatment that blocks two specific proteins (GDF8 and activin A) with GLP-1 therapy leads to larger improvements in blood sugar control and cholesterol levels than GLP-1 therapy by itself.

14

Pro

0

Against

Evidence from Studies

Supporting (1)

14

Community contributions welcome

14

GDF8 and activin A blockade protects against GLP-1–induced muscle loss while enhancing fat loss in obese male mice and non-human primates

Randomized Controlled Trial

Animal

2025 May 13

When obese monkeys got a weight-loss drug (GLP-1) plus a treatment that stops muscle loss, they lost more fat and stayed healthier overall — suggesting their blood sugar and cholesterol improved too.

Contradicting (0)

0

Community contributions welcome

No contradicting evidence found

Gold Standard Evidence Needed

According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.

Source Study

GDF8 and activin A blockade protects against GLP-1–induced muscle loss while enhancing fat loss in obese male mice and non-human primates

Score: 14

DOI: 10.1038/s41467-025-59485-9

Similar Assertions

In obese male primates, combining a drug that blocks two specific muscle-regulating proteins with semaglutide leads to greater increases in muscle mass and more fat loss than semaglutide alone, along with improved blood sugar and cholesterol levels after 20 weeks of treatment.

14

0

77%

In obese male mice and non-human primates, blocking two specific proteins (GDF8 and activin A) while using a GLP-1 receptor agonist helps maintain or increase muscle mass and enhances fat loss, leading to better body composition and improved metabolic indicators like lower liver fat and healthier blood lipids.

14

0

76%